Entropy completes Cohort 1 dosing in BED trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
All six participants in this cohort successfully received both administrations of the treatment, achieving a controlled psychedelic response. The results indicate that IV-infused psilocin may offer advantages over traditional oral therapies, including better control and shorter treatment durations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- Entropy files new US patent for IBS program
- TRP 8802 delivers 75% breakthrough response in IBS
- TRP-8803 delivers repeatable, high-intensity effect
- FY25 R&D Tax Incentive received
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
Later from Entropy Neurodynamics
- DSMB Clears TRP 8803 to Advance to Cohort 2
- 100% Clinical improvement, 50% Remission in BED study
- South Africa Grants ENP Broad Fibromyalgia Patent to 2043
- 72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
- 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics